Table 2. Outcome analysis.
| Results | Total | Only TKI | Concomitant TKI and bisphosphonates | |
|---|---|---|---|---|
| Median PFS (months) | 6 | 4 | 7 | P=0.0011a HR for progression 0.3528 95% CI of ratio 0.1889 to 0.6588 |
| Progression reached | 91% (69/76) | 100% (27/27) | 86% (42/49) | P=0.039b |
| Median OS (months) | 11 | 7 | 17 | P=0.022a HR for survival 0.5229 95% CI of ratio 0.3004 to 0.9101 |
| Death reached | 87% (66/76) | 100% (27/27) | 80% (39/49) | P=0.0118b |
| Partial response | 31% (22/72) | 16% (4/25) | 38% (18/47) | P=0.028c Relative risk: 1.505 95% CI of relative risk 1.082 to 2.094 |
| Stable disease | 38% (27/72) | 40% (10/25) | 36% (17/47) | |
| Progressive disease | 32% (24/72) | 44% (12/25) | 26% (12/47) | |
| Proportion of patients who received second-line targeted therapy after progression on first line | 42% (29/69) | 37% (10/27) | 46% (19/41) |
Abbreviations: CI=confidence interval; HR=hazard ratio; OS=overall survival; PFS, progression-free survival; TKI=tyrosine kinase inhibitor
a
Kaplan–Meier analysis and log-rank for comparison of curves.
b
Fisher exact test.
c
Fisher exact test partial response vs stable disease vs progressive disease.